Provided by Tiger Trade Technology Pte. Ltd.

Aethlon Medical

4.84
+0.626114.87%
Post-market: 4.25-0.5856-12.11%18:06 EST
Volume:3.29M
Turnover:15.29M
Market Cap:3.68M
PE:-0.07
High:4.95
Open:4.33
Low:4.22
Close:4.21
52wk High:84.40
52wk Low:3.42
Shares:761.20K
Float Shares:720.00K
Volume Ratio:165.31
T/O Rate:456.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-68.1067
EPS(LYR):-85.7749
ROE:-191.39%
ROA:-54.79%
PB:0.64
PE(LYR):-0.06

Loading ...

Aethlon Medical Reports Hemopurifier Removes Inflammatory Extracellular Vesicles in Long COVID Study

Reuters
·
Yesterday

Maxim Group Reaffirms Their Hold Rating on Aethlon Medical (AEMD)

TIPRANKS
·
Nov 14

Aethlon Medical Reports Q2 Cost Reduction and Ongoing Cancer Trial Progress

Reuters
·
Nov 13

Aethlon Medical Q2 EPS $(3.74) Misses $(3.66) Estimate

Benzinga
·
Nov 13

Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update

THOMSON REUTERS
·
Nov 13

Aethlon Medical Inc - Qtrly Loss per Share $3.74

THOMSON REUTERS
·
Nov 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 12

Aethlon Medical Inc expected to post a loss of $3.66 a share - Earnings Preview

Reuters
·
Nov 08

Aethlon Medical Inc. to Report Fiscal Second Quarter Results

Reuters
·
Nov 07

Aethlon Medical Regains Nasdaq Compliance After Stock Surge

TIPRANKS
·
Nov 06

Aethlon Medical Inc - Regains Compliance With Nasdaq Minimum Bid Price - SEC Filing

THOMSON REUTERS
·
Nov 06

Aethlon Medical Faces Nasdaq Non-Compliance Notice

TIPRANKS
·
Oct 23

Aethlon Medical Faces Nasdaq Delisting After Failing Minimum Bid Price Requirement

Reuters
·
Oct 23

Aethlon Medical trading halted, news pending

TIPRANKS
·
Oct 18

Aethlon Medical Inc - Authorizes 1-for-10 Reverse Stock Split - SEC Filing

THOMSON REUTERS
·
Oct 16

Aethlon Medical Announces 1-for-10 Reverse Stock Split Effective October 16, 2025

Reuters
·
Oct 16

BRIEF-Aethlon Medical's Hemopurifier® Shows Changes In Extracellular Vesicles, Extracellular Micrornas, And T Cell Numbers In Australian Oncology Clinical Trial

Reuters
·
Oct 07

Aethlon Medical Announces Promising Early Data from Australian Clinical Trial of Hemopurifier® in Cancer Patients Resistant to Anti-PD-1 Therapy

Reuters
·
Oct 07

Aethlon Medical Announces New Share Structure Update

TIPRANKS
·
Sep 13

Aethlon Medical Inc. Announces $4.5 Million Public Offering of Common Stock and Warrants

Reuters
·
Sep 10